HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

By Lipton Allan   Goodman Laurie   Leitzel Kim   Cook Jennifer   Sperinde Jeff   Haddad Mojgan   Köstler Wolfgang   Huang Weidong   Weidler Jodi   Ali Suhail   Newton Alicia   Fuchs Eva-Marie   Paquet Agnes   Singer Christian   Horvat Reinhard   Jin Xueguang   Banerjee Joyee   Mukherjee Ali   Tan Yuping   Shi Yining   Chenna Ahmed   Larson Jeff   Lie Yolanda   Sherwood Thomas   Petropoulos Christos   Williams Stephen   Winslow John   Parry Gordon   Bates Michael  

Breast Cancer Research and Treatment, Vol. 141, Iss. 1, 2013-08 ,pp. : 43-53

Springer Publishing Company

Access to resources Recommend Favorite

α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling

By              

Molecular Medicine Reports, Vol. 9, Iss. 3, 2014-01 ,pp. : 993-998

Spandidos Publications

Access to resources Recommend Favorite

The role of overexpressed HER2 in transformation

By Neve R.M.   Lane H.A.   Hynes N.E.  

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 9-13

Springer Publishing Company

Access to resources Recommend Favorite

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

By Weigelt Britta  

Breast Cancer Research and Treatment, Vol. 122, Iss. 1, 2010-07 ,pp. : 35-43

Springer Publishing Company

Access to resources Recommend Favorite

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

By Crafter Claire   Vincent John P.   Tang Eric   Dudley Phillippa   James Neil H.   Klinowska Teresa   Davies Barry R.  

International Journal of Oncology, Vol. 47, Iss. 2, 2015-08 ,pp. : 446-454

Spandidos Publications

Access to resources Recommend Favorite